Sujay Kango - Infinity Pharmaceuticals Executive Vice President Chief Commercial Officer
| INFIDelisted Stock | USD 0.04 0.03 42.86% |
President
Mr. Sujay Kango is no longer Executive Vice President Chief Commercial Officer of Infinity Pharmaceuticals Inc. effective January 6 2017. Prior to joining Infinity Mr. Kango has served as Executive Vice President and Chief Commercial Officer since April 2015. Prior to joining Infinity Mr. Kango most recently served from April 2011 to March 2015 as vice president global marketing sales operations and business analytics at Onyx Pharmaceuticals an Amgen subsidiary and a pharmaceutical company where he led the global Onyx proteasome inhibitor franchise including Kyprolis and oprozomib and cochaired the OnyxBayer executive committee responsible for oversight of the companies global kinase inhibitor franchise. Prior to Onyx from January 2006 to March 2011 he held several leadership positions at Merck Co. a pharmaceutical company including vice president hepatitis franchise and vice president oncology integrated business unit. Prior to Merck from November 1990 to May 2005 Mr. Kango held various commercial and marketing roles of increasing responsibility at Johnson Johnson and ScheringPlough each of which is a pharmaceutical company. Mr. Kango serves as a director of Cancer Care of New Jersey since 2015.
| Age | 42 |
| Tenure | 9 years |
| Professional Marks | MBA |
| Phone | 617 453 1000 |
| Web | https://www.infi.com |
Infinity Pharmaceuticals Management Efficiency
The company has return on total asset (ROA) of (0.607) % which means that it has lost $0.607 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (35.2135) %, meaning that it created substantial loss on money invested by shareholders. Infinity Pharmaceuticals' management efficiency ratios could be used to measure how well Infinity Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities.The company currently holds 917 K in liabilities with Debt to Equity (D/E) ratio of 0.13, which may suggest the company is not taking enough advantage from borrowing. Infinity Pharmaceuticals has a current ratio of 4.08, suggesting that it is liquid enough and is able to pay its financial obligations when due. Debt can assist Infinity Pharmaceuticals until it has trouble settling it off, either with new capital or with free cash flow. So, Infinity Pharmaceuticals' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Infinity Pharmaceuticals sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Infinity to invest in growth at high rates of return. When we think about Infinity Pharmaceuticals' use of debt, we should always consider it together with cash and equity.
Similar Executives
| Showing other executives | PRESIDENT Age | ||
| Nick Galli | CytomX Therapeutics | N/A | |
| Jacqueline Papkoff | Assembly Biosciences | 61 | |
| Timothy Trost | Chimerix | 55 | |
| Lloyd Rowland | CytomX Therapeutics | 61 | |
| Pinaki Niyogy | Instil Bio | 46 | |
| Christopher Keenan | CytomX Therapeutics | N/A | |
| Bonne Adams | TRACON Pharmaceuticals | 47 | |
| Cynthia Ladd | CytomX Therapeutics | 61 | |
| Steven Perrin | Eledon Pharmaceuticals | 58 | |
| David Houck | Assembly Biosciences | 61 | |
| Uri Lopatin | Assembly Biosciences | 45 | |
| Janet LeeSheriff | Instil Bio | N/A | |
| Leslie Robbins | CytomX Therapeutics | N/A | |
| Heather KnightTrent | Chimerix | N/A | |
| Steven Knox | Assembly Biosciences | N/A | |
Management Performance
| Return On Equity | -35.21 | |||
| Return On Asset | -0.61 |
Infinity Pharmaceuticals Leadership Team
Elected by the shareholders, the Infinity Pharmaceuticals' board of directors comprises two types of representatives: Infinity Pharmaceuticals inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Infinity. The board's role is to monitor Infinity Pharmaceuticals' management team and ensure that shareholders' interests are well served. Infinity Pharmaceuticals' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Infinity Pharmaceuticals' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Joseph Pearlberg, Vice President - Clinical Development | ||
| Melissa Hackel, Vice President - Finance | ||
| William Bertrand, Executive Vice President General Counsel | ||
| Vito Palombella, Chief Scientific Officer and Executive VP | ||
| Jeffrey Berkowitz, Independent Director | ||
| Seth JD, Chief VP | ||
| Lawrence Bloch, CFO, Executive Vice President Chief Business Officer | ||
| Norman Selby, Lead Outside Independent Director | ||
| Jose Baselga, Independent Director | ||
| Samuel Agresta, Chief Medical Officer | ||
| Michael Venuti, Independent Director | ||
| Stephane Peluso, Chief Officer | ||
| MD Ilaria, Chief Officer | ||
| Jayne Kauffman, Sr Coordinator | ||
| Michael Kauffman, Independent Director | ||
| Eric Lander, Independent Director | ||
| David Beier, Independent Director | ||
| Julian Adams, President of RandD | ||
| Anthony Evnin, Independent Director | ||
| Gwendolyn Fyfe, Independent Director | ||
| Sujay Kango, Executive Vice President Chief Commercial Officer | ||
| Ian Smith, Independent Director | ||
| Adelene Perkins, Chairman of The Board, CEO and Pres | ||
| MD JD, Pres Treasurer |
Infinity Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Infinity Pharmaceuticals a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -35.21 | |||
| Return On Asset | -0.61 | |||
| Operating Margin | (15.70) % | |||
| Current Valuation | (9.46 M) | |||
| Shares Outstanding | 90.76 M | |||
| Shares Owned By Insiders | 2.36 % | |||
| Shares Owned By Institutions | 23.48 % | |||
| Number Of Shares Shorted | 2.21 M | |||
| Price To Earning | (1.63) X | |||
| Price To Book | 8.03 X |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Risk vs Return Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in census. Note that the Infinity Pharmaceuticals information on this page should be used as a complementary analysis to other Infinity Pharmaceuticals' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Headlines Timeline module to stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity.
Other Consideration for investing in Infinity Stock
If you are still planning to invest in Infinity Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Infinity Pharmaceuticals' history and understand the potential risks before investing.
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
| FinTech Suite Use AI to screen and filter profitable investment opportunities | |
| CEOs Directory Screen CEOs from public companies around the world | |
| Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments | |
| Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites |